Integrin antagonist - Bayer
Latest Information Update: 25 Feb 2003
Price :
$50 *
At a glance
- Originator Bayer
- Class
- Mechanism of Action Integrin alphaVbeta3 antagonists; Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis; Vascular restenosis
Most Recent Events
- 25 Feb 2003 No development reported - Preclinical for Coronary artery restenosis in Europe (unspecified route)
- 25 Feb 2003 No development reported - Preclinical for Vascular restenosis in Europe (unspecified route)
- 08 Mar 2001 Preclinical development for Coronary artery restenosis in Europe (Unknown route)